TFEB and Birt-Hogg-Dubé syndrome: Importantly, overexpression of TFEB in Trametinib-treated UOK-257 cells, derived from a kidney tumor of a patient with BHD syndrome, resulted in a significant recovery of the clonogenic potential in 2D cultures and an increased resistance to cell death in 3D spheroids, suggesting that the Trametinib effect is mediated, at least in part, by modulation of TFEB levels.